The Resistance Abilities of Some Bacillus Species to Gastrointestinal Tract Conditions: Whole Genome Sequencing of the Novel Candidate Probiotic Strains Bacillus clausii BA8 and Bacillus subtilis BA11
Food Science & Nutrition · 2025-02 · 13 (2)
DOI: 10.1002/fsn3.70018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food Science & Nutrition, online erschienen am 05.02.2025. Verfasst von Nursel Söylemez-Milli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Industrial and Technological Application and Research Center Bolu Abant Izzet Baysal University Bolu Turkey. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aims to investigate the resistance of potential probiotic Bacillus species to various conditions in the gastrointestinal (GI) tract and their safety characteristics. MALDI‐TOF MS identified all tested strains with a good safety score of ≥ 2.0; the strains demonstrated the capacity to pass through the Gl tract, exhibiting a reduction of > 6 log/CFU live cells. Furthermore, they exhibited varying survival rates in an acidic environment (pH 2.0–3.0) and the presence of Ox‐Bile (1% w/v) ( p < 0.05). Following exposure to pH 3.0 and Ox‐Bile, the survival rate of Bacillus spp. ranged between 85.94% and 91.24% and 87.30% and 91.54%, respectively. The results of the in vitro experiments showed that the six Bacillus strains had comparable characteristics (e.g., tolerance to GI track enzyme, auto‐aggregation ability) to the reference probiotic strain Lactiplantibacillus plantarum LA15. The auto‐aggregation results of the B. clausii BA8 strain, which has demonstrated resistance to GI tract conditions, were also noteworthy. This strain showed 72.32% after 2 h and 74.55% at the end of 5 h. Most suitable for use as probiotic strains B. clausii BA8 and B. subtilis BA11, sequenced via Illumina NovaSeq, showed average nucleotide identity (ANI) values of 98.1% and 97.8%, respectively. The genome annotation of B. clausii and B. subtilis with Prokka revealed 4,498,248‐4,215,606 bp genome length, 44%–43% GC content, and 110–26 contigs, respectively. B. clausii BA8 has been comprehensively characterized, is of low risk for human consumption, and has been recommended as a potential probiotic strain. However, further in vivo experimentation is required to confirm these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Scientific Industrial and Technological Application and Research Center Bolu Abant Izzet Baysal University Bolu Turkey.
- Department of Food Processing, Vocational School of Burdur Food, Agriculture and Livestock BurdurMehmet Akif Ersoy University Burdur Turkey.
- Department of Gastronomy and Culinary Arts, School of Tourism and Hospitality Management Ardahan University Ardahan Turkey.
ORCID-Profile: Nursel Söylemez-Milli, Pelin Ertürkmen, Duygu Alp Baltakesmez
Zitieren
APA
Söylemez-Milli, N., Ertürkmen, P., & Alp Baltakesmez, D. (2025). The Resistance Abilities of Some Bacillus Species to Gastrointestinal Tract Conditions: Whole Genome Sequencing of the Novel Candidate Probiotic Strains Bacillus clausii BA8 and Bacillus subtilis BA11. Food Science & Nutrition, 13(2). https://doi.org/10.1002/fsn3.70018
Vancouver
Söylemez-Milli N, Ertürkmen P, Alp Baltakesmez D. The Resistance Abilities of Some Bacillus Species to Gastrointestinal Tract Conditions: Whole Genome Sequencing of the Novel Candidate Probiotic Strains Bacillus clausii BA8 and Bacillus subtilis BA11. Food Science & Nutrition. 2025;13(2). doi:10.1002/fsn3.70018
BibTeX
@article{SylemezMilli2025,
author = {Söylemez-Milli, Nursel and Ertürkmen, Pelin and Alp Baltakesmez, Duygu},
title = {The Resistance Abilities of Some Bacillus Species to Gastrointestinal Tract Conditions: Whole Genome Sequencing of the Novel Candidate Probiotic Strains Bacillus clausii BA8 and Bacillus subtilis BA11},
journal = {Food Science & Nutrition},
year = {2025},
volume = {13},
number = {2},
doi = {10.1002/fsn3.70018}
}
EUVIMED